Interferon gamma release assay

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

QIAGEN’s New Generation of QuantiFERON TB Test Gains Chinese Approval and Renewed WHO Recommendation

Retrieved on: 
Monday, February 7, 2022
Research, Medical Supplies, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Policy, Chinese Academy of Medical Sciences COVID-19 vaccine, Knowledge, LTBI, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Senior, RNA, QFT, Automation, Growth, GDF, QIAGEN, Protein, Research, Solution, HIV, Infection, Molecular diagnostics, Interferon gamma release assay, Technology, Budget, U.S. Securities and Exchange Commission, Global, Diagnosis, Institute, Blood, UNITAID, SEC, Method, DNA, Life, Stop TB Partnership, Institute of Biophysics, Chinese Academy of Sciences, Central business district, QuantiFERON, NMPA, IGRA, Non-functional testing, Disease, Diabetes, Immunodeficiency, National Medical Products Administration, WHO, Medicine, Tuberculosis, TST, Pharmaceutical industry, Vaccine, Insight, TB, Academy, Pharma

Since 2013, more than 1.5 million people in China have been tested for active TB infection using the proprietary QuantiFERON technology.

Key Points: 
  • Since 2013, more than 1.5 million people in China have been tested for active TB infection using the proprietary QuantiFERON technology.
  • The WHO has renewed its recommendation that blood-based Interferon-Gamma Release Assays (IGRA) are an alternative for the diagnosis of TB infection, in addition to the Tuberculin Skin Test (TST).
  • QIAreach QFT was launched in late 2021 and was recently approved by the Global Funds Expert Review Panel Diagnostics (ERPD).
  • "The world needs new technologies and methods to contest TB and QIAGENs IGRA technology is playing a crucial role here.

QIAGEN Expands QuantiFERON Portfolio in the Fight Against TB

Retrieved on: 
Thursday, January 6, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Knowledge, Global, Blood, COVID-19, Severe acute respiratory syndrome coronavirus 2, Gold, QGEN, Food, Regulation of tobacco by the U.S. Food and Drug Administration, GDF, Immunity, Growth, Traction, Research, QFT, Patient, NYSE, DNA, Vaccination, Interferon gamma release assay, Centers for Disease Control and Prevention, Life, The Global Fund to Fight AIDS, Tuberculosis and Malaria, U.S. Securities and Exchange Commission, Deep Ellum, Dallas, Tuberculosis, Public sector, Protein, QuantiFERON, Automation, UNITAID, SEC, FDA, Molecular diagnostics, Pregnancy, RNA, Budget, TB, Gamma ray, Technology, COVID-19 vaccine, Stop TB Partnership, European, IGRA, Solution, QIAGEN, Center, CDC, Vaccine, Insight, Pharma, Academy

A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma that is released from T-cells that have come into contact with TB bacteria.

Key Points: 
  • A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma that is released from T-cells that have come into contact with TB bacteria.
  • We are determined to further expand the range of applications for our immune response technology in the coming years.
  • QIAGEN is experiencing strong customer interest in the QuantiFERON SARS-CoV-2 assay, which was launched in December 2021 and has now received a European CE mark.
  • For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

QIAGEN Launches Novel QIAreach QuantiFERON-TB Tuberculosis Test for High-Burden Regions

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, Medical Supplies, Health, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Other Health, Calibration, Molecular diagnostics, Union, Life, Richard Estick, List of life sciences, Technology, Commission on Sustainable Development, COVID-19, Budget, Lung, Diagnosis, QGEN, Stop TB Partnership, NYSE, Growth, Transport, Tuberculosis, RNA, Annual report, Disease, Lists of disasters, Weather, Knowledge, U.S. Securities and Exchange Commission, Infection, CEO, QIAGEN, Patient, CE, QuantiFERON, Automation, Clinical, Conference, TB, Protein, Partnership, Interferon gamma release assay, ZAMBART Project, Blood, Solution, IGRA, DNA, Marketing, Maintenance, Data management, Heating, ventilation, and air conditioning, Medical imaging, Pharmaceutical industry

QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.

Key Points: 
  • QIAGEN will focus on regions that face a high burden of the disease, and where getting access to lab infrastructure and resources for testing are limited.
  • With QIAreach QuantiFERON-TB we have taken a great step towards leaving no one behind when facing a deadly disease like tuberculosis that is preventable and curable.
  • A quantum leap from the traditional TB skin test, QuantiFERON-TB uses blood samples to test for interferon-gamma molecules released from T-cells that have come into contact with TB bacteria.
  • QIAreach QuantiFERON-TB runs these tests on the digital eHub and eStick system, a true walkaway solution with random access and no calibration or maintenance.

QIAGEN’s QuantiFERON®-TB Gold Plus to be Adopted for Latent TB Testing in Nigeria

Retrieved on: 
Wednesday, February 19, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Infectious diseases, Clinical trials, Tuberculosis, Medicine, Infectious diseases, Medical specialties, Latent tuberculosis, Qiagen, Interferon gamma release assay, QuantiFERON, Tuberculosis in India

QIAGEN has partnered with Nigerias National Tuberculosis & Leprosy Control Program (NTBLCP) to adapt World Health Organisation (WHO) guidelines and provide guidance to healthcare professionals on dealing with latent TB.

Key Points: 
  • QIAGEN has partnered with Nigerias National Tuberculosis & Leprosy Control Program (NTBLCP) to adapt World Health Organisation (WHO) guidelines and provide guidance to healthcare professionals on dealing with latent TB.
  • Nigeria is the first high-burden country to exclusively embrace modern blood tests, called interferon gamma release assays (IGRAs), for latent TB screening of at-risk individuals in tuberculosis control programs.
  • Nigeria is first in Africa to adopt the Global End TB strategy by incorporating TB prevention in their national TB guidelines.
  • To finally provide both TB treatment and prevention for Nigerians is a major step forward towards global health equity and accelerating TB decline in Nigeria.

QIAGEN and Tecan Announce Collaboration to Streamline Preanalytical Processing of QuantiFERON-TB Gold Plus

Retrieved on: 
Friday, March 8, 2019
Health, Biotechnology, Infectious diseases, Medical devices, Research, Science, Tuberculosis, Chemistry, Medical specialties, Physical sciences, QuantiFERON, Interferon gamma release assay, Latent tuberculosis, Qiagen, IGRA, Assay, Interferon, Metallurgical assay

The Fluent instruments will be supplied directly to laboratories through Tecans Life Sciences Business.

Key Points: 
  • The Fluent instruments will be supplied directly to laboratories through Tecans Life Sciences Business.
  • QIAGENs fourth-generation QuantiFERON-TB Gold Plus is the modern gold standard for latent tuberculosis (TB) detection based on world leading interferon gamma release assay (IGRA) technology.
  • The two parties are working together to optimize a solution that standardizes and automates the manual steps in liquid handling for the aliquoting of samples.
  • Front-end automation solutions also offer laboratories efficient automation of single tube collection for QuantiFERON, and thereby create efficiency in the lab and improve the patient blood collection experience.